Thomas F. Gajewski to Mice, Transgenic
This is a "connection" page, showing publications Thomas F. Gajewski has written about Mice, Transgenic.
Connection Strength
1.347
-
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602.
Score: 0.133
-
Primary murine CD4+ T cells fail to acquire the ability to produce effector cytokines when active Ras is present during Th1/Th2 differentiation. PLoS One. 2014; 9(11):e112831.
Score: 0.092
-
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol. 2013 Oct; 55(3-4):283-91.
Score: 0.083
-
Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS One. 2011; 6(9):e24931.
Score: 0.074
-
Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-?1 phosphorylation. J Immunol. 2011 Jan 15; 186(2):784-90.
Score: 0.070
-
Beta-catenin does not regulate memory T cell phenotype. Nat Med. 2010 May; 16(5):513-4; author reply 514-5.
Score: 0.067
-
Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells. J Immunol Methods. 2008 Feb 29; 331(1-2):94-102.
Score: 0.057
-
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells. Cell Immunol. 2007 Jun; 247(2):95-102.
Score: 0.056
-
T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol. 2006 Nov; 7(11):1166-73.
Score: 0.053
-
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol. 2006 Oct 01; 177(7):4521-9.
Score: 0.053
-
Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cells. J Immunol. 2005 Nov 01; 175(9):5581-5.
Score: 0.049
-
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol. 2005 Apr 15; 174(8):4670-7.
Score: 0.048
-
ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. J Immunol. 2005 Mar 15; 174(6):3416-20.
Score: 0.047
-
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004 Feb 01; 64(3):1140-5.
Score: 0.044
-
Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes. Biochem Biophys Res Commun. 2003 Dec 19; 312(3):691-6.
Score: 0.043
-
Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol. 2003 Nov 01; 171(9):4574-81.
Score: 0.043
-
CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol. 2001 Sep 15; 167(6):3123-8.
Score: 0.037
-
Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol. 2001 Mar 15; 166(6):3900-7.
Score: 0.036
-
The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit Rev Oncog. 1999; 10(3):247-60.
Score: 0.031
-
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med. 1998 Jul 06; 188(1):205-10.
Score: 0.030
-
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8.
Score: 0.025
-
Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015 Jun 25; 6:7458.
Score: 0.024
-
Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses. Cancer Cell. 2014 Jan 13; 25(1):37-48.
Score: 0.022
-
CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013 May; 123(5):1999-2010.
Score: 0.021
-
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
Score: 0.014
-
Production of TH1 and TH2 cell lines and clones. Curr Protoc Immunol. 2006 May; Chapter 3:3.13.1-3.13.15.
Score: 0.013
-
An adenoviral vector for probing promoter activity in primary immune cells. J Immunol Methods. 2006 Apr 20; 311(1-2):19-30.
Score: 0.013
-
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med. 2003 Jun 16; 197(12):1721-30.
Score: 0.010
-
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002 Dec; 17(6):737-47.
Score: 0.010
-
Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 2001 Sep 01; 167(5):2555-60.
Score: 0.009
-
Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells. Proc Natl Acad Sci U S A. 2000 Dec 05; 97(25):13784-9.
Score: 0.009
-
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol. 2000 May 01; 164(9):4433-42.
Score: 0.008
-
B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol. 1998 Nov 15; 161(10):5268-75.
Score: 0.008
-
Helper T cell differentiation is controlled by the cell cycle. Immunity. 1998 Aug; 9(2):229-37.
Score: 0.007
-
Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. J Immunol. 1997 Nov 15; 159(10):4665-75.
Score: 0.007